Enobia Pharma announced completion of enrollment for its Phase 2 study of ENB-0040 for the treatment of hypophosphatasia. HPP is a rare genetic disease characterized primarily by defective bone mineralization caused by a deficiency in the enzyme tissue nonspecific alkaline phosphatase (TNSALP). This study is a randomized, open-label, multicenter, multinational, dose-ranging, concurrent control study that will evaluate the safety and efficacy of ENB-0040 in adolescents and adults with HPP. The study is expected to be completed in the second half of 2011.
ENB-0040 is a subcutaneous enzyme replacement therapy of TNSALP fused to a bone-targeting peptide. It is designed to directly target TNSALP to the bone in order to correct the enzyme deficiency, which could lead to restoration of normal bone mineralization.
For more information call (514) 596-2901 or visit www.enobia.com.